omeprazole + amoxicillin

Omeprazole + amoxicillin is a dual therapy combination regimen utilized for the eradication of *Helicobacter pylori* infection, particularly in the context of duodenal and peptic ulcers. Omeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by covalently binding to and inhibiting the H+/K+-ATPase enzyme system at the secretory surface of the gastric parietal cell. By increasing gastric pH, omeprazole creates a more favorable environment for the stability and antimicrobial activity of amoxicillin. Amoxicillin is a beta-lactam antibiotic that exerts its bactericidal effect by inhibiting the synthesis of the bacterial cell wall through binding to penicillin-binding proteins (PBPs). This specific clinical study led by the National Taiwan University Hospital evaluates the efficacy of this dual therapy while accounting for the CYP2C19 genotype, which dictates the metabolic rate of omeprazole and significantly influences the clinical success of the eradication regimen.

Other names

omeprazole and amoxicillin dual therapy